Study title: Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial.(Statistical Data Included) Article from: Journal of the American Academy of Child and Adolescent Psychiatry,2001 | RIDDLE, MARK A.; REEVE, ELIZABETH A.; YARYURA-TOBIAS,JOSE A.; YANG, HWA MING; CLAGHORN, JAMES L.; GAFFNEY, GARY; GREIST,JOHN H.; HOLLAND, DONNA; McCONVILLE, BRIAN J.; PIGOTT, TERESA; WALKUP, JOHN T.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Mental Disorders [F03] | |||||
| Brands: Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: FLUVOXAMINE | |||||
| ATC code: | |||||
| Document link: Bayer Pharma_Fluvoxamine Maleate_Riddle MA_2001_publication.pdf | |||||
| Document date: 2011-09-15 | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |